This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
Johns Hopkins University
Baltimore, Maryland, United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Cleveland Clinic Mellen Center
Cleveland, Ohio, United States
Incidence of adverse events (safety and tolerability)
Incidence of AEs through Day 29
Time frame: Day of Treatment to End of DLT Evaluation Period (28 Days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.